A Study of LY4175408 in Adults with Advanced or Metastatic Solid Tumors

The trial enrolled 241 participants diagnosed with Cancer. Both female and male individuals were included, encompassing the demographic groups classified by age‑range codes 3 and 4. The study population comprised patients considered vulnerable, reflecting the inclusion of individuals commonly regarded as at increased risk. Enrollment was based on the sponsor’s predefined selection criteria targeting patients with the specified diagnosis; no additional lifestyle requirements such as diet or physical activity were stipulated in the provided information.

The study is a phase 1 clinical investigation of LY4175408 in participants with advanced or metastatic solid Cancer. Enrollment will commence on 30 October 2025 and is planned to conclude by 29 May 2029. Each participant will first attend a screening visit to verify eligibility criteria, followed by the administration of the investigational product according to the protocol schedule. Subsequent follow-up visits will be conducted at predetermined intervals to evaluate safety, tolerability, pharmacokinetics, and disease status, with the final assessment occurring at the end-of-study visit. Participant involvement extends from the screening appointment through the completion of the end-of-study assessments, encompassing the entire treatment and observation periods defined by the study protocol. Individual participation may be discontinued prematurely if protocol‑specified safety or disease‑progression criteria are met.